Who Owns 111 Company?

Who Owns 111, Inc.?

Understanding a company's ownership is key to grasping its strategy and accountability. An IPO marks a significant shift, moving a company from private to public ownership. This article examines the ownership of 111, Inc. (NASDAQ: YI), a major integrated online and offline healthcare platform in China.

Founded in 2010, 111, Inc. began with an online retail pharmacy, aiming to improve healthcare access in China. Its growth has led to a comprehensive platform including online consultation, prescription services, and a retail pharmacy network, alongside its wholesale operations. The company's market capitalization stood at $60.02 million as of July 30, 2025.

Let's explore the ownership journey of 111, Inc., from its founders to its major investors and public shareholders.

The foundation of 111, Inc. was laid in 2010 by Dr. Gang Yu and Mr. Junling Liu. Their combined expertise in technology and e-commerce, including their prior success with YHD.com, positioned them to lead the company. This chapter delves into their roles and the initial ownership structure.

Founding Visionaries

Dr. Gang Yu and Mr. Junling Liu are the co-founders of 111, Inc. Their extensive experience in the tech and e-commerce industries, including previous ventures, shaped the company's early direction.

Key Leadership Roles

Dr. Yu serves as Co-Founder and Executive Chairman, while Mr. Liu holds the positions of Co-Founder, Chairman of the Board, and Chief Executive Officer. This dual leadership guides the company's strategic operations.

Pre-IPO Experience

Before establishing 111, Inc., both founders were instrumental in the success of YHD.com, a prominent e-commerce platform in China. This prior experience provided valuable insights into market dynamics.

Dual-Class Share Structure

Upon its IPO in September 2018, the company adopted a dual-class share structure. This included Class A ordinary shares with one vote per share and Class B ordinary shares with fifteen votes per share.

Founder Control

Immediately before the IPO, Dr. Yu and Mr. Liu held all Class B shares. This arrangement granted them substantial voting power, ensuring their continued influence over the company's trajectory.

Voting Power Concentration

Following the IPO, the founders collectively controlled approximately 92.3% of the total voting power. This significant concentration underscored their commitment and vision for the company's future.

The founders' extensive backgrounds, including Dr. Yu's roles at Dell Inc. and Amazon.com, and Mr. Liu's executive positions at Dell Inc., Avaya China, and Lucent Technologies Asia, provided a strong foundation for 111, Inc. Their prior success in co-founding YHD.com, a leading e-commerce entity in China, further solidified their expertise. The implementation of a dual-class share structure at the time of the September 2018 IPO, with Class B shares carrying fifteen votes each, ensured that the founders, Dr. Gang Yu and Mr. Junling Liu, maintained significant control. This structure allowed them to wield 92.3% of the total voting power immediately after the IPO, reflecting their substantial stake and commitment to the company's strategic direction, a key element in understanding the Growth Strategy of 111.

Founders and Early Ownership Details

The ownership structure of 111, Inc. was significantly influenced by its founders, Dr. Gang Yu and Mr. Junling Liu, from its inception in 2010.

• Dr. Gang Yu and Mr. Junling Liu co-founded 111, Inc. in 2010.
• Dr. Yu holds the roles of Co-Founder and Executive Chairman.
• Mr. Liu is the Co-Founder, Chairman of the Board, and Chief Executive Officer.
• Both founders have prior experience co-founding YHD.com, a major Chinese e-commerce company.
• The company implemented a dual-class share structure at its IPO in September 2018.
• Class B shares, held by the founders, carry 15 votes per share, while Class A shares have 1 vote per share.
• Immediately post-IPO, the founders controlled approximately 92.3% of the company's total voting power.

The ownership journey of 111, Inc. began with its public debut on the Nasdaq Global Market in September 2018. This Initial Public Offering (IPO) established the company's presence as a publicly traded entity, setting the stage for its subsequent ownership evolution.

Following its IPO, 111, Inc. has seen its ownership structure adapt, with a notable concentration of voting power remaining with its founders. As of September 13, 2024, co-founders Dr. Gang Yu and Mr. Junling Liu collectively held a significant stake, owning 42.7% of the company's total issued share capital. This level of ownership, while substantial, reflects the typical dilution that can occur when companies raise additional capital after their public offering. The company's financial performance, with net revenues of RMB 3.5 billion (US$486.3 million) in the first quarter of 2025, underscores the ongoing operational activity that influences its ownership dynamics.

Key Stakeholders in 111, Inc.

Understanding who owns 111 company involves looking at both its founders and institutional investors. These groups play a crucial role in the company's direction and future growth.

• Founders: Dr. Gang Yu and Mr. Junling Liu maintain significant beneficial ownership.
• Institutional Investors: A notable percentage of shares are held by various investment firms.
• Major Institutional Shareholders (as of March 31, 2025): Renaissance Technologies Llc, Connor, Clark & Lunn Investment Management Ltd., Deuterium Capital Management, LLC, Morgan Stanley, and JPMorgan Chase & Co.
• Significant Individual Institutional Holdings: FIL Ltd (7.963% as of February 13, 2025) and Napean Trading & Investment Co Singapore PTE Ltd (4.598% as of February 11, 2025).
• Publicly Traded Status: The company is publicly traded on the Nasdaq Global Market under the ticker 'YI.'

The current Board of Directors for 111, Inc. is led by its co-founders, Dr. Gang Yu and Mr. Junling Liu, who also hold executive leadership roles. The board includes several independent directors, ensuring a degree of oversight. A recent change saw Mr. Yang 'Luke' Chen appointed as a director in November 2024, following Dr. Leon Lian Yong Chen's resignation.

The ownership and control of 111 company are significantly concentrated due to its dual-class share structure. Class B ordinary shares carry fifteen votes per share, while Class A ordinary shares have one vote each. All Class B shares are held by the co-founders, Dr. Gang Yu and Mr. Junling Liu. This arrangement grants them approximately 92.2% to 92.3% of the total voting power, effectively ensuring their continued control over major corporate decisions and limiting the influence of Class A shareholders. This structure is a key aspect of the 111 company structure, impacting its governance and potential for future changes in control.

Understanding 111 Company Ownership

The voting power at 111 company is heavily weighted towards its founders. This dual-class share system is a critical factor in understanding who controls the company and how decisions are made.

• Founders Dr. Gang Yu and Mr. Junling Liu hold Class B shares, each with 15 votes.
• Class A shareholders have 1 vote per share.
• The founders collectively wield approximately 92.2% to 92.3% of the total voting power.
• This structure solidifies founder control and influences the company's strategic direction.
• For more on the company's background, see the Brief History of 111.

In recent years, the ownership landscape of 111, Inc. has seen significant shifts, notably with co-founders Dr. Gang Yu and Mr. Junling Liu demonstrating strong conviction by purchasing company shares from their personal funds in September 2024. This action underscored their belief in the company's intrinsic value, with the co-founders collectively holding 42.7% of the total issued share capital as of that announcement, solidifying their substantial stake and influence.

The company's financial performance in 2024 marked a pivotal moment, achieving its first-ever annual operational profitability and positive operating cash flow. This turnaround was driven by a substantial reduction in operating expenses, which decreased by 31% year-over-year, totaling RMB 827.1 million. Despite a slight dip in net revenues to RMB 14.4 billion, the focus on efficiency resulted in a significant bottom-line improvement of RMB 332.7 million compared to 2023. This positive trajectory continued into the first quarter of 2025, with stable net revenues of RMB 3.5 billion (US$486.3 million) and sustained operational profitability and positive operating cash flow, reflecting a robust operational strategy.

Leadership and Governance

Mr. Yang 'Luke' Chen's appointment as a director in November 2024 highlights the company's focus on financial acumen within its management structure. This move follows Dr. Leon Lian Yong Chen's resignation, indicating a strategic reinforcement of financial oversight.

Innovation and Intellectual Property

The acquisition of four new patents in 2024, expanding the company's patent portfolio to 28, underscores a commitment to technological advancement. These investments are crucial for enhancing operational efficiency and maintaining a competitive edge.

Financial Turnaround and Stability

Achieving operational profitability in 2024, with an income from operations of RMB 2.1 million, signifies a major financial achievement. This was supported by a 31% reduction in operating expenses, demonstrating improved financial management.

Strategic Vision and Market Position

The company's strategic vision centers on empowering China's healthcare value chain through digital transformation. This focus, coupled with sustained profitability in early 2025, positions the company for continued growth and influence in the sector. Understanding this strategy is key to grasping the Marketing Strategy of 111.